Chen, Zhen
Yu, Danlei
Owonikoko, Taofeek K. http://orcid.org/0000-0002-7724-7728
Ramalingam, Suresh S.
Sun, Shi-Yong http://orcid.org/0000-0002-0117-8826
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA223220, CA245386, CA233259, CA21769)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 8 March 2021
Revised: 24 September 2021
Accepted: 1 October 2021
First Online: 11 October 2021
Competing interests
: SSR is on consulting/advisory board for AstraZeneca, Amgen, BMS, Merck, Roche, Tesaro and Amgen. TKO is on consulting/advisory board for Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, Takeda, Bristol-Myers Squibb, MedImmune, Amgen, AstraZeneca and Boehringer Ingelheim. Other authors declare that they have no conflict of interest.